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Abstract
Conventional parenteral injection of vaccines is limited in its ability to induce locally-produced immune responses
in the respiratory tract, and has logistical disadvantages in widespread vaccine administration. Recent studies
suggest that intranasal delivery or vaccination in the respiratory tract with recombinant viral vectors can enhance
immunogenicity and protection against respiratory diseases such as influenza and tuberculosis, and can offer more
broad-based generalized protection by eliciting durable mucosal immune responses. Controlled aerosolization is a
method to minimize vaccine particle size and ensure delivery to the lower respiratory tract. Here, we characterize
the dynamics of aerosolization and show the effects of vaccine concentration on particle size, vector viability, and
the actual delivered dose of an aerosolized adenoviral vector. In addition, we demonstrate that aerosol delivery of
a recombinant adenoviral vaccine encoding H1N1 hemagglutinin is immunogenic and protects ferrets against
homologous viral challenge. Overall, aerosol delivery offers comparable protection to intramuscular injection, and
represents an attractive vaccine delivery method for broad-based immunization campaigns.
Introduction
Conventional parenteral delivery of flu vaccines is lim-
ited in its ability to induce locally-produced immune
responses in the respiratory tract as well as its capacity
for efficient widespread distribution [1,2]. Recent studies
evaluated intranasal delivery of recombinant vector-
based influenza vaccines as an alternative route of deliv-
ery that may enhance safety, efficacy, and ease of admin-
istration [3-6]. Vaccination in the respiratory tract may
enhance protection against respiratory diseases such as
influenza, tuberculosis, and measles, and may provide
more generalized protection by inducing long-lasting
mucosal immune responses [7,8]. Studies have also
shown that mucosal immunity induced via intranasal
delivery provides cross-protection against heterologous
strains [9-15], and enhances heterosubtypic immunity
for protection against multiple influenza A subtypes
[9,10,16,17]. Other logistical advantages of an intranasal
vaccine include the reduced risk of infection and con-
tamination due to the non-use of needles and syringes,
and avoiding the need for disposal strategies of sharps
after mass vaccination campaigns [18-20].
The currently licensed intranasal vaccine FluMist™ is
a live-attenuated virus administered using a Becton-
Dickenson AccuSpray™ device which generates a high-
speed spray of large vaccine particles, with a mass med-
ian aerosol diameter (MMAD) > 70 μm. With particle
size and speed being key factors determining aerosol
deposition in the airway, these high-speed, large particle
sprays are often trapped in the external nares and do
not navigate to the internal airways which are the pri-
mary target of vaccination. Furthermore, droplets depos-
ited in the nose can drip out or roll back toward the
pharynx causing unpleasant sensations, diminishing
acceptability of the vaccine [7]. In contrast, controlled
aerosolization helps to minimize vaccine particle size
variability and ensures delivery to the lower respiratory
tract and internal target airways [21]. In animals, aerosol
vaccination is currently used globally to immunize poul-
try against Newcastle disease and shows promise of suc-
cessful immunization in fowls and pigs against a variety
of diseases including fowlpox, infectious bronchitis, hog
cholera, pseudorabies, erysipelas, gastroenteritis, pasteur-
ellosis, and mycoplasmosis [19]. Notably, aerosol
measles vaccination of 4 million Mexican schoolchildren
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64% (similar to subcutaneous administration) and an
overall efficacy of 96%, with excellent public acceptance
and fewer side effects than subcutaneous vaccination
[22]. However, while aerosol vaccination shows advan-
tages in eliciting protective immune responses as well as
cost-efficacy of administration, more studies are needed
to further characterize the method and ensure that it is
a safe and practical alternative.
Here, we elucidate the dynamics of aerosolization by
analyzing particle size, vector viability, and actual deliv-
ered dose of an aerosolized adenoviral vector. This vec-
tor has been previously used alone or in combination
with DNA prime immunizations to protect against lethal
influenza challenges in mice and ferrets [23,24]. In addi-
tion, we compare the efficacy of aerosol vaccination to
intramuscular (IM) injection of this recombinant adeno-
viral (Ad) vaccine encoding seasonal H1N1 immunogens
against homologous challenge in ferrets.
Results indicate that vaccine concentration influences
aerosol size, viability, and actual delivered dose, and
should be considered in designing an optimal aerosol
vaccination regimen. Results from the influenza chal-
lenge study indicate that aerosol vaccination elicits
humoral immune responses and protects against H1N1
influenza challenge. Furthermore, the use of aerosol as
the modality of vaccination has previously shown mini-
mal to no lasting pathology in the lung, and is compar-
able to IM injection in immunogenicity and protection.
Materials and methods
PARI eFlow
® nebulizer device
The PARI eFlow
® device is a portable, electronic aerosol
platform developed primarily to deliver liquid pharma-
ceutical therapies in a clinical setting [25-27]. The PARI
eFlow
® aerosol device generates aerosols via a laser
drilled membrane that is actuated via a piezoelectric
crystal which pumps liquid through the membrane at
relatively high velocity. This device was utilized in this
study to deliver a biologic-based vaccine to the respira-
tory tract.
Particle size characterization
Empty Ad vector solutions were diluted in final formu-
lation buffer (FFB) at seven different log concentrations,
ranging from 10
5 to 10
11 particle units (PU)/mL, in
order to establish size distribution characteristics of the
aerosolized particles produced by the PARI eFlow
®
device. Three samples of 1 mL aliquots of each Ad con-
centration were aerosolized into a small plexiglass
chamber using the PARI eFlow
® device. An automated
particle sizer (Aerodynamic Particle Size Model 3321,
TSI Instruments, St. Paul, MN) was used to sample the
generated atmosphere within the chamber and produce
size and relative distribution estimates.
Adenoviral aerosol viability
Effects of the aerosol generation using the PARI device
upon the relative viability of the Ad vector were
unknown prior to this study. In order to determine the
effect of aerosolization on the viability of an Ad vector
and estimate the actual inhaled dose, empty Ad vector
solutions were diluted at seven different log concentra-
tions (as done in the particle size characterization
experiment). Three samples of 1 mL aliquots were aero-
solized as above, and the resultant aerosol was collected
into an All-Glass Impinger (AGI) (Ace Glass, Vineland,
NJ) containing 10 mL phosphate-buffered saline (PBS).
The liquid capture of aerosol particles within the impin-
ger contained an air sample that represented the atmo-
spheric concentration of the Ad generated by the
aerosol device. Immunofluorescence assays were per-
formed in triplicate on collected samples to measure
infectious titers post-aerosolization [28]. A non-aeroso-
lized control for each concentration was also included.
The fluorescent forming unit (FFU) results from the
sampled aerosols were directly compared with the FFU
content of the “pre” aerosol starting concentrations
(expressed in FFU/l liquid starting concentration) in
order to determine viral efficiencies after aerosol genera-
tion. The unitless factor (viral efficiency factor; Fe),
defined as a ratio of the starting concentration (FFU/l
liquid inoculum) to the aerosol concentration (FFU/l
aerosol) was used to express the relative viability of the
Ad in aerosol (Table 1). While the magnitude of this
value does not have a direct biological interpretation,
comparison across conditions would reveal differential
viral loss.
Construction of recombinant Ad5 vaccine encoding
hemagglutinin (HA)
An Ad5-based first-generation vaccine expressing HA
was constructed as described previously [29]. HA immu-
nogen was derived from the A/Brisbane/59/2007 H1N1
isolate, a strain used in 2008-2009 Flumist™ trivalent
intranasal vaccine [30]. Briefly, PacI-linearized shuttle
vectors containing the influenza immunogen were
recombined with the right side of Ad5 genomic DNA
carried in a cosmid by use of Cre recombinase (Nova-
gen, Madison, Wis.). The resulting recombinant was
ethanol precipitated, dissolved in Tris-EDTA, and trans-
fected into HEK 293 cells. Recombinant Ads were
observed based on plaque formation 10 to 14 days after
transfection. Viruses were amplified, purified two times
through a CsCl gradient, and stored in PBS plus 15%
glycerol at -20°C.
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4-6 month old male, Fitch ferrets (Triple F Farms, Sayre,
PA), sero-negative for exposure to currently circulating
H1N1, H3N2, and B flu strains were housed and cared
for at BIOQUAL, Inc. (Rockville, MD). These facilities
are accredited by the American Association for the
Accreditation of Laboratory Animal Care (AAALAC)
International and meet NIH standards as set forth in
the Guidelines for Care and Use of Laboratory Animals
[31]. Prior to the start of the study, a temperature trans-
ponder (Biomedic Data Systems, Inc., Seaford, DE) was
implanted into the neck of each ferret. Two groups of 7
ferrets were immunized twice at weeks 0 and 3 with an
Ad5 vaccine encoding the HA gene from the A/Bris-
bane/59/2007 isolate at a dose of 1 × 10
10 PU. One
group of ferrets received the Ad5 vaccine via IM injec-
tions in the upper thigh muscle while another group
received the same vaccine via aerosol delivery using a
PARI eFlow
® nebulizer (Starnberg, Germany). Control
ferrets were also immunized with empty Ad vectors via
aerosol delivery.
For aerosol administration, ferrets were anesthetized
with IM injections of 5-10 mg/kg ketamine and 0.5-1.0
mg/kg xylazine, and placed in a BSL-2 biosafety cabinet.
With the PARI eFlow
® device set up according to man-
ufacturer’s instructions, 1 mL of the vaccine was poured
into the medication reservoir, and a modified facemask
was applied to the ferret, ensuring a seal. The device
was then activated and automatically deactivated after
all of the liquid volume containing the vaccine was
expended. The facemask was applied for an additional
minute to ensure inhalation of any remaining aerosol.
Hemagglutination inhibition (HI) assay
Sera were treated with receptor-destroying enzyme
(RDE) by diluting one part serum with three parts
enzyme and incubated overnight in a 37°C water bath.
The enzyme was inactivated by a 30 min. incubation at
56°C followed by addition of six parts PBS for a final
dilution of 1/10. HI assays were performed in V-bottom
96-well plates using four hemagglutinating units (HAU)
of virus and 1% horse erythrocytes as previously
described [32]. Ferret sera were tested against homolo-
gous H1N1 influenza strain A/Brisbane/59/2007.
Production of pseudotyped lentiviral vectors and
measurement of neutralizing antibodies
Production of pseudotyped lentiviral vectors for H1N1
and neutralization of pseudotyped viruses were per-
formed as previously described [33].
Ferret challenge experiments
Ferrets were challenged three weeks after their second
immunization with ~10
5 50% Egg Infectious Dose
(EID50) of the H1N1 influenza strain A/South Dakota/6/
2007 which is 99% homologous to A/Brisbane/59/2007.
This virus had been expanded in 10-day old chicken
eggs at BIOQUAL (Rockville, MD) from a seed stock
obtained from the CDC (Atlanta, GA). The diluted virus
stock was inoculated intranasally (in a volume of 0.25
ml per nostril) into ferrets that had been anesthetized
with ketamine/xylazine. Ferrets were observed for clini-
cal signs twice daily while weight and temperature mea-
surements were recorded once daily by technicians blind
to treatment groups. Ferrets that lost more than 25%
body weight or displayed severe clinical signs of infec-
tion (e.g. extreme lethargy or neurological impairment)
were euthanized during the study. Remaining ferrets
were euthanized on day 14 post challenge. Challenge
experiments were performed in BSL-2 conditions and
conducted at BIOQUAL, Inc. laboratories, which are
approved for use by the USDA and CDC.
Nasal washes were obtained pre-challenge and on days
2,5, and 7 post-challenge, and viral titers were deter-
mined using a real-time PCR assay as previously
described [34]. Briefly, RNA was isolated from nasal
washes and RT-PCR was performed using TaqMan
reagents (Applied Biosystems, Foster City, CA) along
with primers and probes covering a highly conserved
region within the nucleoprotein gene. The detection
range for this assay is 20-10
7 copies/ml. Viral load data
were analyzed using Tukey’s Honestly Significant
Table 1 Effect of aerosolization on Ad viability.
PS01 PS02 PS03
Cs (FFU/ml)C a (FFU/ml) Fe Ca (FFU/ml)F e Ca (FFU/ml)F e
1.00E+08 1.76E+02 1.76E-06 n.d. n.d. 5.64E+01 5.64E-07
1.00E+09 2.74E+02 2.74E-07 5.04E+02 5.04E-07 9.05E+02 9.05E-07
1.00E+10 4.77E+03 4.77E-07 1.22E+04 1.22E-06 9.55E+03 9.55E-07
1.00E+11 n.d. n.d. 6.25E+04 6.25E-07 1.61E+05 1.61E-06
Mean(PS) ± S.E. 8.37E-07 ± 2.69E-07 7.84E-07 ± 1.28E-07 1.01E-06 ± 1.09E-07
Aerosol viability estimates for Adf.11D LN05224 from each independent experiment (PS01, PS02, PS03) using logarithmic starting concentrations (Cs) and the
corresponding aerosol concentration (Ca) obtained from a proximity sampler located within a characterization chamber. The viral efficiency factor (Fe), a unitless
ratio of the Cs and Ca, is used as an indicator of the dilution and associated loss of biologic activity during the process of aerosolization of the solution
containing the adenovirus during characterization. The overall mean Fe for all samples attempted was 8.8 × 10
-7.
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between immunized groups and controls. For each ana-
lysis, P values < 0.05 were considered statistically
significant.
Results
Particle size characterization
Characterization of the aerosolized Ad particle size was
performed using a time-of-flight aerodynamic particle
sizer (APS 3321, TSI Inc.). Proximity sampling was per-
formed using the APS in a 16 liter plexiglass chamber.
Resulting particle size distributions (Figure 1) showed
MMADs fluctuated according to the relative concentra-
tion of the Ad present in the liquid carrier solution; the
estimated MMAD ranged from 2.8 up to 6.5 μm, with
relatively smaller MMAD ranges (3.1-2.8 μm) in genera-
tion events that incorporated higher Ad concentrations
(10
10-10
11). The shifting MMAD is highlighted by a
relatively stable geometric standard deviation (1.5-1.8)
across all Ad concentrations used, indicating a minimal
heterodispersity in the size distributions generated.
Particle size limitations for respirability in the ferret is
unknown, but the majority of mass represented in most
of the size distributions shown would be considered
respirable in species of similar size, weight, and anatomy
[35].
Viability of aerosolized adenoviral vectors
Results show the mean viral efficiency factor was rela-
tively consistent over all concentrations, suggesting that
the viability of the Ad will not be dramatically affected
by the starting vector dose. Notably, the efficiency for
this virus is not unusually low relative to the method of
generation. A predictive dose delivered via inhalation
can be derived from the mean viral efficiency factor,
through estimation of the respiratory minute volume of
the species, and the estimated aerosol concentration
achieved with a particular viral starting concentration
used. The nominal total titer administered to the ferrets
was measured at 1.0E+10 PFU; the corresponding
inhaled doses for the species by applying the viral effi-
ciency factor estimate was 1.14E+04 PFU/animal.
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Figure 1 Particle size analysis and dose optimization. Graphs of particle size distributions of aerosolized Ad 11D LN05224 at logarithmic titers
used (FFU/ml). Ordinate axis represents the mass of particles between logDp and d logDp (Dp = particle diameter). The transecting line for each
distribution represents the mass median aerodynamic diameter (MMAD) and geometric standard deviation (sg), respectively. The abscissa axis
represents particle size in μm.
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encoding HA
To compare the immune responses elicited by aerosol
delivery to those by intramuscular injection, HI and
pseudotype assays were performed on sera collected
three weeks after the two immunizations by either
route. As shown in Table 2, IM injection elicited moder-
ately higher responses than aerosol delivery against both
homologous and heterologous H1N1 viruses according
to HI assays, although these differences were not found
to be statistically significant via analysis by an unpaired
t-test. Concurrently, the pseudotype inhibition assay also
indicated that aerosol delivery elicited similar neutraliz-
ing responses as IM injection.
Viral load reduction in ferrets challenged with H1N1 A/
South Dakota/2007
To assess the extent of viral replication in the upper
respiratory tract after challenge, nasal washes were per-
formed at multiple time points following challenge and
virus was quantified by RT-PCR (Figure 2). Significant
reduction of viral loads was observed in aerosol-immu-
nized groups compared to controls by day 2 post-chal-
lenge (pc) (P < 0.013). By day 5 pc, both immunization
methods had significantly reduced viral loads compared
to controls, (P< 0. 0 0 1f o rA E ,P=0.007 for IM). The
reduction of viral loads was more prominent on day 7
pc as both immunized groups reached the minimum
detection level (20 copies/mL nasal wash) while the
virus persisted in the control group.
Discussion
Aerosol delivery is a potential alternative to parenteral
injection for vaccine administration and may be
Table 2 Antibody titers of ferrets immunized with Ad5
encoding H1N1 HA.
HI Assay (GMT) Pseudotype Assay (IC50)
NC Brisbane NC Brisbane
Ad5-Control: AE
a <2 0 <2 0 ——
Ad5-Brisbane (×2): AE
a 33 215 1064 2045
Ad-Brisbane (×2): IM
a 98 390 1593 1805
a N=7
HI and pseudotype lentiviral assays were performed on ferret serum collected
three weeks after the second immunization, against H1N1 strains of A/
Brisbane/59/2007 and A/New Caledonia/20/99.
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Figure 2 Viral load reduction in H1N1 A/South Dakota/06/2007 challenged ferrets. Viral loads were measured in H1N1-challenged ferrets
at days 2,5 and 7 post-challenge. Bars indicate mean values of the log10 viral load, while error bars indicate standard error. Statistical differences
were analyzed using Tukey’s Honestly Significant Difference (HSD) method, and are indicated by asterisks where * represents a p-value between
0.05 and 0.01, ** indicates 0.01-0.001, and *** indicates < 0.001. Error bars indicate standard error.
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the site of infection against respiratory pathogens such
as influenza [7,8]. Here we characterize important fac-
tors for optimizing such delivery including particle size,
vector viability, and actual delivered dose of an aeroso-
lized Ad vector. We also compare the efficacy of aerosol
vaccination to IM injection against a seasonal H1N1
challenge in ferrets.
Results from the particle size characterization experi-
ment suggest that the concentration of the Ad solution
has an effect on the size of the particle generated. This
is important since particle size affects the site of
deposition in the respiratory tract which will then
influence biological responses [35]. The respiratory sys-
tem and prevailing anatomy of the ferret is considered
susceptible to particle sizes consistent with respirability
estimates in mammals such as dogs and cats in con-
trast to similarly sized rodent species [36,37]. High
concentrations of Ad resulted in generally smaller
aerosolized particles despite the nebulizer’sd e s i g nt o
produce nominal 4 μm particles. This may be due to a
clogging effect in which Ad precipitates on the nebu-
lizing membrane, leaving residues which may hamper
the efficiency of aerosolization. This hypothesis is sup-
ported by the observation that at high concentrations,
the process of aerosolization took considerably longer
than at low concentrations despite frequent changes
and cleaning of nebulizing membranes. While other
studies have similarly shown the effect of concentra-
tion on aerosol size [38], membrane “clogging” has not
been previously documented and should be evaluated
more closely.
Results from the seasonal influenza challenge study
suggest that both aerosol and IM delivery of our Ad5
vaccine elicit similar levels of influenza-specific antibody
responses, and are also comparable in reducing viral
replication in the lungs of challenged ferrets. This is
consistent with a previous study where we demonstrated
robust immunogenicity and protection against lethal
H5N1 influenza challenges in the ferret model [8] and is
further supported by other recent challenge studies in
mice [7,14]. While aerosolization may be comparable to
IM delivery in serum antibody responses and viral load
reduction, it may have significant advantages. One such
advantage is the induction of local mucosal immune
responses which may contribute to broader protection
against heterologous strains and subtypes [4,7,8],
whereas parenteral vaccination is incapable of inducing
these types of responses [1]. In addition, aerosol delivery
may enhance acceptability of vaccination since it does
not require needles and causes less discomfort than
intranasal sprays [7]. Lastly, aerosol delivery is a safe,
reliable, and economically feasible vaccine delivery
platform that does not have the attendant safety risks of
injections.
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